Chris Spivey

Pharmaceutical Technology Europe® spoke with Gautam Shetty from Congruence Medical Solutions, a US drug delivery device company, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Pharmaceutical Technology Europe® spoke with Dr. Rainer Schmidt from Galvita AG, an excipient manufacturer based in Switzerland, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

CPHI Barcelona has strong showing as bio/pharma industry moves confidently into 2024.

Chris Spivey, editorial director, hosts a wide ranging discussion on the COVID-19 pandemic response, future government communications, and healthcare funding for mRNA with experts Dr. Kate Broderick, Chief Innovation Officer, Maravai LifeSciences and Dr. Tom Madden, President & CEO at Acuitas Therapeutics. Highlights include supply chain modalities, ensuring a fully trained manufacturing workforce, combining delivery with gene editing innovations, epigenetic approaches to modulate gene expression moving toward the clinic. We conclude with the huge potential for RNA expression of monoclonal antibodies and protein replacement applications.

Government provides a spoonful of sugar, and genuine leadership, for good medicines.

If the Alliance for mRNA Medicines (AMM) tested the waters in June 2023 at the BIO Conference in Boston, then they engaged in a full-fledged triathlon in September, in the heat and humidity of Washington, DC.

Extensive research on various gene editing techniques could inform the future of mRNA therapies.

An mRNA conversation about the recent past, current hot topics, and probable future.

Experts discuss the promise of personalized cancer vaccines through the inherent nimbleness of mRNA platform.

Highlights from a wide ranging discussion on COVID-19 pandemic response from Kate Broderick, Chief Innovation Officer at Maravai LifeSciences, and Tom Madden, President & CEO at Acuitas Therapeutics.

mRNA may be a modality whose chief advances are yet to come.

Automation can be balanced with operator oversight.

The prestigious award, worth €20,000 (US$22,000), goes to Maurice Michel of the Science for Life Laboratory at Karolinska Institutet, Stockholm, Sweden.

Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.

World leaders have set ambitious goals to respond more swiftly to the next pandemic, including the US goal to design, test, and review a new vaccine just 100 days after a pandemic declaration.

BIO is a powerful business development conference that can help make a lot of deals become reality.

The collaboration between Samsung Biologics and Pfizer will focus on long-term biosimilars manufacturing.

Vaccine nationalism strengthens viruses and poses deadly risks for all involved.

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

Jane True, vice-president of mRNA Commercial Strategy & Innovation and Global Pandemic Security Lead, Pfizer, shares her perspective on how mRNA will shift commercial models in the pharmaceutical industry.

In this episode of Drug Digest, Pharmaceutical Technology editors discuss the advantages and savings that continuous manufacturing may offer as well as the very real obstacles that might make a fully continuous process not feasible, especially in biologics manufacturing.

Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.

Bob Girton, partner at Edgewater, discusses best practices for how pharma manufactures should incorporate sustainability into their operations.

Actions combatting the next pandemic must be diverse, reliable, and sustainable.

Nicole Lewis, PVP Program Manager at Boston Children's Hospital, discusses the science behind precision vaccines, a form of personalized vaccines.

Marcel Baumann, business development director at Recipharm, discusses soft mist inhaler technology from the show floor at the World Vaccine Conference.

Limitations in production platforms have impeded continuous manufacturing for advanced therapies.

What can we take away from Pfifzer's acquisition of Seagen?

Decreasing vein to vein time saves lives.

The further we pursue CGT, the more variability we need to account for in order to engineer consistency into these new products.